Lung cancer, one of the leading causes of cancer-related deaths globally, often goes undetected until its advanced stages. However, a groundbreaking innovation by scientists at the University of Cambridge has introduced a simple and cost-effective urine test that could revolutionize early lung cancer detection.
The test, developed by researchers from the Department of Chemical Engineering and Biotechnology and the Early Cancer Institute, focuses on identifying specific cell proteins associated with lung cancer in its earliest stages. This innovative approach has been successfully tested on mice, and human trials are expected to commence soon.
Professor Ljiljana Fruk, a key member of the research team, explained that cancerous tissues release specific proteins that signal damage. These proteins are detected using a two-part probe injected into the body. The smaller part of the probe, released into urine, reacts with a silver solution to reveal potential early signs of cancer. This unique mechanism provides a simple way to monitor lung tissue changes through urine color.
Funded by Cancer Research UK, this test aims to offer a more affordable alternative to expensive scans. It is especially promising for high-risk groups and those with a history of cancer recurrence. If successful, this urine test could transform cancer diagnostics, enabling timely treatment and improving survival rates.
